КЛИНИЧЕСКАЯ ЗНАЧИМОСТЬ ДОМИНИРУЮЩИХ РОДОВ РЕЗИДЕНТНОГО МИКРОБИОМА ОПУХОЛЕЙ ПОЧКИ

Аннотация

Об авторах

Список литературы

1. Frankel A.E., Coughlin L.A., Kim J., Froehlich T.W., Xie Y., Frenkel E.P., Koh A.Y. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy
in melanoma patients. Neoplasia. 2017; 19 (10): 848-55. DOI: 10.1016/j.neo.2017.08.004.
2. Matson V., Fessler J., Bao R., Chongsuwat T., Zha Y., Alegre M.L., Luke J.J., Gajewski T.F. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018; 359 (6371): 104-8. DOI: 10.1126/science.aao3290.
3. Dey P., Ray Chaudhuri S. Cancer-Associated Microbiota: From Mechanisms of disease causation to microbiota-centric anti-cancer approaches. Biology (Basel). 2022; 11 (5): 757. DOI: 10.3390/ biology11050757.
4. Poore G.D., Kopylova E., Zhu Q., Carpenter C., Fraraccio S., Wandro S. et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020; 579 (7800): 567-74. DOI: 10.1038/s41586-020-2095-1.
5. Deryagina V.P., Ryzhova N.I., Krivosheeva L.V., Golubeva I.S., Savluchinskaya L.A., Khochenkov D.A. iNOS expression and biosynthesis of nitric oxide metabolites in the course of tumor growth of different histogenesis. Uspekhi molekulyarnoy onkologii. 2016; 3 (3): 73-80. DOI: 10.17650/2313-805X-2016-3-3-73-80. (in Russian)
6. Kovaleva O., Podlesnaya P., Rashidova M., Samoilova D., Petrenko A., Zborovskaya I. et al. Lung microbiome differentially impacts survival of patients with non-small cell lung cancer depending on tumor stroma phenotype. Biomedicines. 2020; 8 (9): 349. DOI:
10.3390/biomedicines8090349.
7. Gao Y., Zhou S., Xu Y., Sheng S., Qian S.Y., Huo X. Nitric oxide synthase inhibitors 1400W and L-NIO inhibit angiogenesis pathway of colorectal cancer. Nitric Oxide. 2019; 83: 33-9. DOI: 10.1016/j. niox.2018.12.008.
8. Fahey J.M., Girotti A.W. Nitric oxide-mediated resistance to photodynamic therapy in a human breast tumor xenograft model: Improved outcome with NOS2 inhibitors. Nitric Oxide. 2017; 62: 52-61. DOI: 10.1016/j.niox.2016.12.003.
9. Ekmekcioglu S., Grimm E.A., Roszik J. Targeting iNOS to increase efficacy of immunotherapies. Hum. Vaccin. Immunother. 2017; 13 (5): 1105-8.
DOI: 10.1080/21645515.2016.1276682.
10. Lopez-Rivera E., Jayaraman P., Parikh F., Davies M.A., Ekmekcioglu S., Izadmehr S. et al. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res. 2014; 74 (4): 1067-78.
DOI: 10.1158/0008-5472.CAN-13-0588.
11. Garrido P., Shalaby A., Walsh E.M., Keane N., Webber M., Keane M.M. et al. Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. Oncotarget. 2017; 8 (46): 80568-88.
DOI: 10.18632/oncotarget.19631.
12. Chen C.N., Hsieh F.J., Cheng Y.M., Chang K.J., Lee P.H. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer.
Journal of surgical oncology. 2006; 94 (3): 226-33. DOI: 10.1002/ jso.20372.
13. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Baroni G., Taddei A., Taddei G.L. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol. Oncol. 2004; 92 (3): 806-12. DOI: 10.1016/j. ygyno.2003.12.023.
14. Ropponen K.M., Kellokoski J.K., Lipponen P.K., Eskelinen M.J., Alanne L., Alhava E.M., Kosma V.M. Expression of inducible nitric oxide synthase in colorectal cancer and its association with prognosis. Scandinavian journal of gastroenterology. 2000; 35 (11): 1204-11.
DOI: 10.1080/003655200750056709.
15. Li C., Li H., Jiang Z., Zhang T., Wang Y., Li Z., Wu Y., Ji S., Xiao S., Ryffel B., Radek K.A., Xia Z., Lai Y. Interleukin-33 increases antibacterial defense by activation of inducible nitric oxide synthase in skin. PLoS Pathog. 2014; 10(2):e1003918. DOI: 10.1371/journal. ppat.1003918.
16. Tate D.J.Jr., Patterson J.R., Velasco-Gonzalez C., Carroll E.N., Trinh J., Edwards D., Aiyar A. et al. Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells. Int. J. Biol. Sci. 2012; 8(8):1109-20. DOI: 10.7150/ijbs.4694.
17. Muglia V.F., Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol. Bras. 2015; 48 (3): 166-74. DOI: 10.1590/0100-3984.2013.1927.

Ключевые слова